Dr Anthony Hannan and his team also found that fluoxetine restores the brain's process of neurogenesis - the birth of new neurons - to normal levels, which helps delay the onset of the inherited fatal disease.
People with Huntington's disease have progressive motor problems, cognitive deficits (dementia) and psychiatric symptoms (the most common is depression) that usually start to appear in mid-life. There is no cure and death usually results within 10 to 20 years of symptom onset, or faster in the childhood-onset form of the disease. The disease is caused by a mutation in a single gene and when this defective gene is passed from parent to child, 50 percent of the offspring will inherit the disorder, which can be detected by genetic testing.
Dr Hannan said this discovery was an important step in developing effective treatments to delay the onset of symptoms and the progression of Huntington's disease.
"Now that we've found fluoxetine improves memory problems, or dementia, as well as depression in mice with Huntington's disease, further research can be conducted to see if the drug has the same benefits in humans with the disease," Dr Hannan said.
"We have started discussing arrangements with colleagues to begin human trials to see if fluoxetine, and related drugs, are also effective treatments in people with the disease."
"Fluoxetine's ability to promote the birth of new neurons in the normal and Huntington's brain provides new insight into the biological basis of depression, as well as other brain disorders involving dementia. It also suggests new applications for these antidepressant drugs," he said.
During the study, mice with the Huntington's gene and control mice were treated daily with either fluoxetine
Contact: Merrin Rafferty